Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

British HIV Association guidelines for antiretroviral treatment of HIV-2-positive individuals 2010.

Gilleece Y, Chadwick DR, Breuer J, Hawkins D, Smit E, McCrae LX, Pillay D, Smith N, Anderson J; BHIVA Guidelines Subcommittee.

HIV Med. 2010 Nov;11(10):611-9. doi: 10.1111/j.1468-1293.2010.00889.x. No abstract available.

2.

Guidelines for use of antiretroviral therapy for HIV infected individuals in India (ART guidelines 2008).

Pujari S, Patel A, Joshi SR, Gangakhedkar R, Kumarasamy N, Gupta SB; Expert Panel 2008.

J Assoc Physicians India. 2008 May;56:339-48, 353-71. Review. No abstract available.

PMID:
18700643
3.

The impacts of current antiretroviral therapy regimens on Chinese AIDS patients and their implications for HIV-1 drug resistance mutation.

Zhang M, Han XX, Cui WG, Jia MH, Meng XD, Xing AH, Wu YH, Yang YY, Lu CM, Hu QH, Dai D, Zhang ZN, Shang H.

Jpn J Infect Dis. 2008 Sep;61(5):361-5.

4.

Antiretroviral resistance.

Geretti AM.

J HIV Ther. 2006 Dec;11(4):72-3. No abstract available.

PMID:
17578209
5.

[Antiretroviral therapy in patients infected with HIV-1].

Corti ME.

Medicina (B Aires). 1998;58 Suppl 1:49-56. Spanish. No abstract available.

PMID:
9674248
6.

Virological and immunological impact of non-nucleoside reverse transcriptase inhibitor withdrawal in HIV-infected patients with multiple treatment failures.

Piketty C, Gérard L, Chazallon C, Calvez V, Clavel F, Taburet AM, Girard PM, Aboulker JP; ANRS 107 Puzzle 2 Study Group.

AIDS. 2004 Jul 2;18(10):1469-71.

PMID:
15199325
7.

Clinical, immunological and virological response to different antiretroviral regimens in a cohort of HIV-2-infected patients.

van der Ende ME, Prins JM, Brinkman K, Keuter M, Veenstra J, Danner SA, Niesters HG, Osterhaus AD, Schutten M.

AIDS. 2003 Jul;17 Suppl 3:S55-61.

PMID:
14565610
8.

Long-term analysis of the resistance development in HIV-1 positive patients treated with protease and reverse transcriptase inhibitors: correlation of the genotype and disease progression.

Václavíková J, Weber J, Machala L, Reinis M, Linka M, Brůcková M, Vandasová J, Stanková M, Konvalinka J.

Acta Virol. 2005;49(1):29-36.

PMID:
15929396
9.

Phenotypic and genotypic resistance to nucleoside reverse transcriptase inhibitors in HIV-1 clinical isolates.

Lafeuillade A, Poggi C, Hittinger G, Chadapaud S.

HIV Med. 2001 Oct;2(4):231-5.

10.

Immunovirologic consequences and safety of short, non-structured interruptions of successful antiretroviral treatment.

Sanchez R, Portilla J, Gimeno A, Boix V, Llopis C, Sanchez-Paya J, Merino E, de la Sen ML, Muñoz C, Reus S, Plazas J.

J Infect. 2007 Feb;54(2):159-66. Epub 2006 May 11.

PMID:
16690132
11.

Special considerations regarding antiretroviral therapy and infection prophylaxis in the HIV-infected individual with cancer.

Sparano JA, Kalkut G.

Cancer Treat Res. 2001;104:347-66. Review. No abstract available.

PMID:
11191134
12.

Antiretroviral therapy in human immunodeficiency virus-infected individuals.

Spooner KM.

Adv Intern Med. 1998;43:373-402. Review. No abstract available.

PMID:
9506188
13.

Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy.

Harrigan PR, Hertogs K, Verbiest W, Larder B, Yip B, Brumme ZL, Alexander C, Tilley J, O'Shaughnessy MV, Montaner JS.

Antivir Ther. 2003 Oct;8(5):395-402.

PMID:
14640386
14.

Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy.

Recsky MA, Brumme ZL, Chan KJ, Wynhoven B, Yip B, Dong WW, Heath KV, Montaner JS, Levy AR, Hogg RS, Harrigan PR.

J Infect Dis. 2004 Jul 15;190(2):285-92. Epub 2004 Jun 11.

15.

HIV genotypic resistance testing to optimize antiretroviral prescribing: is there room for improvement?

Uy J, Brooks JT, Baker R, Hoffman M, Moorman A, Novak R; HOPS Investigators.

Antivir Ther. 2007;12(6):957-62.

PMID:
17926650
16.

Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088).

Vray M, Meynard JL, Dalban C, Morand-Joubert L, Clavel F, Brun-Vézinet F, Peytavin G, Costagliola D, Girard PM; Narval Trial Group.

Antivir Ther. 2003 Oct;8(5):427-34.

PMID:
14640390
17.

The challenge of antiretroviral-drug-resistant HIV: is there any possible clinical advantage?

Zaccarelli M, Tozzi V, Perno CF, Antinori A.

Curr HIV Res. 2004 Jul;2(3):283-92. Review.

PMID:
15279592
19.

Guidelines for using antiretroviral agents among HIV-infected adults and adolescents.

Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK; Panel on Clinical Practices for Treatment of HIV.

Ann Intern Med. 2002 Sep 3;137(5 Pt 2):381-433.

PMID:
12617573
20.

Loss of zidovudine related mutations in the reverse transscriptase gene of HIV after switching therapy.

Falkensammer B, El Attal R, Müllauer B, Sarcletti M, Parson W, Dierich MP, Stoiber H.

Eur J Med Res. 2002 Sep 30;7(9):379-86.

PMID:
12435615
Items per page

Supplemental Content

Write to the Help Desk